Vaccine combo aims to supercharge immune attack on HPV-Positive throat cancer
NCT ID NCT05799144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two experimental HPV vaccines (pBI-11 and TA-HPV) to the standard immunotherapy drug pembrolizumab can shrink tumors or slow cancer growth in people with advanced oropharyngeal cancer that is HPV-positive. About 54 adults whose cancer has returned or spread will receive the vaccines and pembrolizumab. The goal is to see if the combination triggers a stronger immune response against the cancer than pembrolizumab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OROPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama Birmingham
RECRUITINGBirmingham, Alabama, 35249, United States
Contact
Contact
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••